Pancreatic Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Pancreatic Cancer Information Center has current, evidence-based information for you. Get the facts about pancreatic cancer prevention, early detection, treatment, and survivorship, and stay up to date with ongoing pancreatic cancer research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Pancreatic Cancer Community is the leading Social Media Application for Pancreatic Cancer patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Patients treated with the combination had the best outcome with an average survival of 6.1 months versus 4.2 months. National Pancreatic Cancer Awareness Month on CancerConnect
Find support, get information, connect with others. FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer
FDA has now granted Orphan Drug Designation to pegylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer.
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse... Caregivers
What is Caregiving and Who are Caregivers? Caregivers are individuals who provide...
Pancreatic Cancer Management
By Diana Price Julie Fleshman knows all about the urgent need for hope that grips... Jack & Jill Late Stage Cancer Foundation
Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the... Moving Bodies, Changing Lives
Moving On Aerobics helps women regain joy of movement and physical fitness after...
Pancreatic Cancer Clinical Trials
INST0802 – Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients with Locally Advanced or Metastatic Pancreatic Cancer
07-111 – A Phase II randomized, double-blind, multicenter trial of Amplimexon plus Gemcitabine versus Gemcitabine plus placebo in patients with metastatic chemotherapy naive pancreatic adenocarcinoma.
MORAb-009 – A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy of MORAb-009 in Conmbination with Gemcitabine in Patients with Advanced Pancreatic Cancer